Skip to main content
Premium Trial:

Request an Annual Quote

Genomics to Play Role In New Memorial Sloan-Kettering Grad School

NEW YORK, Nov. 18 (GenomeWeb News) - When it opens its doors in July 2006, the Louis V. Gerstner, Jr. School of Biomedical Sciences at the Memorial Sloan-Kettering Cancer Center will try to bring together basic cancer research, including genomics and various cell-signaling disciplines, with clinical practice, said Thomas Kelly, director of the Sloan-Kettering Institute and provost of the new graduate school in a statement today.

 

The school hopes to offer a curriculum including a one-year course covering "all aspects" of cancer biology, according to the statement.

 

Named after Louis Gerstner, a board of overseers vice president, philanthropic donor, and president of the board of trustees, the school will be housed in a new research building with "open floor labs" dedicated to chemical biology, immunology, human oncology and pathogenesis, and molecular pharmacology.

 

When the school opens, it will enroll 10-12 students leading to a PhD in cancer biology, said the statement, eventually leading to a total enrollment of 60.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.